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bind to surface nucleolin. Through this binding, treatment 
with HB-19 inhibited tumor development in human breast 
cancer cell line MDA-MB-231 and rhabdoid tumor cell line 
derived from wilms’s tumor in xenograft nude mouse mod-
els. The results show that surface nucleolin acts as an anti-
carcinogenic mediator for HB-19.
Conclusion Based on these discrete functions of surface 
nucleolin, the binding complex of carcinogenic ligands and 
surface nucleolin seems to be competing with that of anti-
carcinogenic ligands and surface nucleolin. Moreover, car-
cinogenic ligands derived from endogenous sources play 
a significant role in human cancer development, and the 
interaction of surface nucleolin with disease-related ligands 
will be a new research subject for the prevention and treat-
ment of various ailments.
Keywords Carcinogenic mediator · eMT · HB-19 · 
Nucleolin · Tipα
Introduction
Nucleolin, with a molecular weight of 105–110 kDa, ini-
tially called C23, is originally one of the 100 distinct pro-
teins: It makes 5–10 % of total nucleolar protein in normal 
rat liver and Novikoff hepatoma ascites cells (Orrick et al. 
1973; Bugler et al. 1982). Human nucleolin cDNA, con-
taining the entire coding region, was isolated from lambda 
gt110 human retinal library, and the human nucleolin gene 
consists of 14 exons and 13 introns on chromosome 2q12-
qter (Srivastava et al. 1990). The translation of the nucleo-
tide sequence predicted a 707-amino acid protein with sev-
eral discrete domains (Srivastava et al. 1989), and amino 
acid sequence analysis of nucleolin revealed three struc-
tural domains: The N-terminal domain contains both highly 
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Purpose Cell-surface nucleolin in human gastric cancer 
cell lines is a receptor for TNF-α-inducing protein (Tipα) of 
Helicobacter pylori. The binding complex of nucleolin and 
Tipα is internalized into the cells and then induces tumor 
progression of human gastric cancer. Surface nucleolin is 
also a receptor of human immunodeficiency virus-1, and 
the anti-HIv pseudopeptide (HB-19) showed anti-carcino-
genic activity in vivo. Surface nucleolin has dual functions 
depending on the ligands: In order to understand the mech-
anisms of surface nucleolin, it is necessary to review sur-
face nucleolin and its relation to carcinogenic ligands and 
anti-carcinogenic ligands. Other ligands can be grouped 
among disease-related ligands, which is an important new 
topic for the prevention of various ailments.
Results and discussion This paper mainly deals with two 
ligands of surface nucleolin, Tipα and pseudopeptide HB-
19. The binding complex of nucleolin and Tipα induces 
expression of TNF-α and chemokine genes and activates 
NF-κB in gastric cancer cells of humans and mice. How-
ever, when human gastric cancer cell line MKN-1 was 
transfected with nucleolin-targeted siRNA, the result was 
inhibition of cell migration and elongation induced by Tipα. 
The amount of surface nucleolin was reduced in membrane 
fraction of the nucleolin knockdown MKN-1 cells, but the 
amount of nucleolin in the cytosol or nuclear fractions of 
the cells did not change. The results indicate that surface 
nucleolin acts as a carcinogenic mediator for Tipα of H. 
pylori. In contrast, both the viral external envelop glycopro-
tein gp120 of HIv and the anti-HIv pseudopeptide HB-19 
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acidic regions and multiple phosphorylation sites; the cen-
tral domain contains four RNA-binding domains (RBD or 
RRM); and the C-terminal domain (RGG or GAR) is rich 
in glycine, arginine, and phenylalanine residues (Ginisty 
et al. 1999). Nucleolin was previously thought to be a sim-
ple RNA-binding protein involved in the organization of 
nucleolar chromatin, packaging of pre-RNA, rDNA tran-
scription, and ribosome assembly by shuttling between 
nucleus and cytoplasm; recent investigation has further 
revealed that nucleolin is involved in modulating transcrip-
tional process, cytokinesis, nucleogenesis, signal transduc-
tion, apoptosis, induction of chromatin decondensation, 
and replication (Srivastava and Pollard 1999).
Although more than 90 % of nucleolin is found in the 
nucleolus, phosphorylated nucleolin is found on the cell 
surface of logarithmically growing simian virus 40-trans-
formed mouse fibroblasts (Pfeifle and Anderer 1983). 
Nucleolin has been classified into nuclear, cytoplasmic, 
and cell-surface nucleolins, depending on location in the 
cells; both nuclear and surface nucleolins are phosphoryl-
ated (Belenguer et al. 1989; Jordan et al. 1994). Nuclear 
nucleolin has pI values between pH 4.0 and pH 6.0, and 
surface/cytoplasmic nucleolin is about pH 4.5. Cytoplasmic 
nucleolin is found in small vesicles that appear to translo-
cate nucleolin to the cell surface, and this translocation is 
temperature dependent. Nucleolin is expressed at the cell 
surface, where it exists in close association with intracellu-
lar actin cytoskeleton, and surface nucleolin is clustered at 
the external side of plasma membrane (Hovanessian et al. 
2000). The half-life of nuclear nucleolin is estimated to 
be more than 8 h, while that of surface nucleolin is <1 h 
(Hovanessian et al. 2010). Surface nucleolin is recently 
attracting great attention as an important receptor of cells 
for numerous ligands derived from various sources.
It is of interest to note that surface nucleolin plays a crit-
ical role in carcinogenesis, since endogenous ligands such 
as midkine, pleiotrophin, P-selectin, and hepatocyte growth 
factor (HGF) are involved in carcinogenesis (Table 1) 
(Kadomatsu and Muramatsu 2004; Reyes-Reyes and Aki-
yama 2008; Tate et al. 2006). In our study on Helicobac-
ter pylori (H. pylori) carcinogenesis, we discovered that 
tumor necrosis factor-α (TNF-α)-inducing protein (Tipα) of 
H. pylori is a carcinogenic factor that induces tumor pro-
motion in vitro and in vivo (Suganuma et al. 2001, 2005). 
It was exciting for us to find that the exogenous ligand Tipα 
binds to surface nucleolin on human gastric cancer cell 
Table 1  Ligands of surface nucleolin
Ligands Sources Reported function References
Carcinogenic
 Midkine endogenous Mitogenic, transformation Kadomatsu and Muramatsu (2004)
 Pleiotrophin endogenous Mitogenic, transformation Kadomatsu and Muramatsu (2004)
 Hepatocyte growth factor endogenous Cancer development Tate et al. (2006)
 K-Ras4B endogenous Cancer development Birchenall-Roberts et al. (2006)
 P-selectin endogenous Signal transduction Reyes-Reyes and Akiyama (2008)
 erbB receptors endogenous Malignant transformation Di Segni et al. (2008)
 Tipα H. pylori Tumor promotion and progression watanabe et al. (2010b)
Anti-carcinogenic
 HB-19 Synthesized Anti-HIv infection, anti-carcinogenic activity Nisole et al. (2002)
 Lactoferrin Cow’s milk Anti-carcinogenic activity Legrand et al. (2004)
 AS1411/GROs Synthesized Anti-carcinogenic activity Ireson and Kelland (2006)
 endostatin endogenous Anti-angiogenic, anti-carcinogenic activities Shi et al. (2007)
 N6L Synthesized Anti-carcinogenic activity Destouches et al. (2011)
Disease-related
 Lipoproteins endogenous Lipid homeostasis Semenkovich et al. (1990)
 Laminin endogenous Neurite outgrowth Kleinman et al. (1991)
 Fructosyllysine endogenous Cell attachment Krantz et al. (1995)
 Group B coxsackievirus CvB viral infection de verdugo et al. (1995)
 Factor J endogenous Complement inhibitor Larrucea et al. (1998)
 HIv HIv viral infection Nisole et al. (1999)
 elongation factor Tu Francisella tularensis Bacterial infection Barel et al. (2008)
 Intimin-γ Escherichia coli O157:H7 Bacterial adherence Sinclair and O’Brien (2002)
 RSv RSv viral infection Tayyari et al. (2011)
 Aβ42 endogenous Alzheimer’s disease Ozawa et al. (2013)
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lines and that internalization of the Tipα and nucleolin com-
plex induces tumor progression and epithelial–mesenchy-
mal transition (eMT) in human gastric cancer (Suganuma 
et al. 2008; watanabe et al. 2013): Our study showed that 
the binding of Tipα to surface nucleolins is an essential step 
for H. pylori carcinogenesis in humans. Hovanessian and 
his colleagues discovered that surface nucleolin serves as a 
low-affinity receptor for human immunodeficiency virus-1 
(HIv-1), and they further demonstrated that treatment with 
anti-HIv pseudopeptide HB-19 inhibits tumor develop-
ment of human breast cancer and rhabdoid tumor cell lines 
in xenograft nude mouse models, mediated through surface 
nucleolin (Destouches et al. 2008; Krust et al. 2011b); HB-
19 treatment partly inhibits metastasis of melanoma cells to 
lymph nodes and lungs (el Khoury et al. 2010). In light of 
this evidence, it is necessary to look at the dual functions 
of surface nucleolin as a carcinogenic mediator and as an 
anti-carcinogenic mediator. This paper reviews the numer-
ous functions of surface nucleolin and the relationship with 
carcinogenic and anti-carcinogenic ligands. Disease-related 
ligands that do not belong to the previous two types may 
show the way of preventing some ailments.
Specificity of surface nucleolin
The presence of surface nucleolin was first suggested by 
endogenously phosphorylated proteins on the surface of 
various cell lines and the phosphoprotein of simian virus 
40-transformed mouse fibroblasts (Pfeifle et al. 1981; Pfei-
fle and Anderer 1983). Surface nucleolin was later identi-
fied in vitro in human hepatocellular carcinoma cell line 
HepG2, and in vivo in angiogenic endothelial cells within 
the vasculature (Semenkovich et al. 1990; Christian et al. 
2003): It is a glycosylated protein found in various cells. 
Since extranuclear nucleolin undergoes N- and O-glyco-
sylations, it may be that glycosylation has a role in regu-
lating the function of nucleolin (Carpentier et al. 2005). 
The N-linked glycosylation of cytoplasmic nucleolin is an 
essential step for the expression of surface nucleolin in var-
ious cells (Losfeld et al. 2009). Recently, Hovanessian and 
his colleagues found that surface nucleolin creates a 500-
kDa protein complex that consists of at least eight other 
proteins: two wnt-related proteins A and B (wNT7A and 
wNT7B); Ku80 autoantigen; signal recognition particle 
(SRP) subunits 68 and 72; receptor for complement compo-
nent gC1q-R/p32, which lacks N-terminal 72 amino acids; 
and ribosomal proteins S4 and S6 (Krust et al. 2011a). The 
features of each protein can be briefly noted as follows: 
wNT7A and wNT7B are implicated in proliferation and 
differentiation of both normal and cancer cells (Kirikoshi 
and Katoh 2002); Ku80 antigen is present on the surface 
of leukemic and solid tumor cell lines, including T and 
B lymphomas, myeloid leukemia, neuroblastoma, rhab-
domyosarcoma, and breast carcinoma cells (Lynch et al. 
2001); SRP68 and 72 are subunits of a ribonucleoprotein 
complex of 7S RNA and 6 proteins, and SRP is involved 
in major cellular machinery (Keenan et al. 2001); gC1q-
R, also known as hyaluronan-binding protein 1 (HABP 
1), plays a significant role in bacterial infections, inflam-
mation, and tumor progression (Bourguignon 2008; Rubin-
stein et al. 2004); S4 and S6 are components of 40S and 
60S ribosomal subunits, which build up ribosomal 80S, and 
many ribosomal protein genes act as cancer genes in zebra 
fish (Amsterdam et al. 2004). In addition, ligand binding to 
surface nucleolin induces high transitory Ca++ membrane 
fluxes in the cells and elevates cell proliferation associated 
with expression of surface nucleolin levels (Losfeld et al. 
2009). All the results show that proliferating cells have sur-
face nucleolin on the plasma membrane and that surface 
nucleolin forms a large protein complex, but the interaction 
between the proteins and surface nucleolin has not been 
clearly established.
Ligands of surface nucleolin
Ligands are isolated from various sources. To make their 
functions clearer, they can be classified into three types, 
carcinogenic, anti-carcinogenic, and disease-related ligands 
(Table 1). Among carcinogenic ligands, midkine (MK) and 
pleiotrophin (PTN) are original heparin-binding growth 
factors, and MK is expressed in a wider rage of human 
carcinoma cells than PTN is (Kadomatsu and Muramatsu 
2004); HGF regulates invasion and growth of carcinoma 
cells (Tate et al. 2006); K-Ras4B protein is a potent onco-
protein present in the nucleoli of both normal and trans-
formed cells (Birchenall-Roberts et al. 2006); P-selectin 
binding to human colon carcinoma cell line Colo-320 
forms a signaling complex with surface nucleolin (Reyes-
Reyes and Akiyama 2008); erbB receptor tyrosine kinases 
are major contributors to malignant transformation, and 
their interaction with nucleolin results in receptor dimeri-
zation and anchorage-independent growth (Di Segni et al. 
2008); Tipα of H. pylori, a carcinogenic factor, will be 
described in more detail shortly (watanabe et al. 2010b).
Among anti-carcinogenic ligands, HB-19 pseudopeptide 
is a potent inhibitor of HIv infection where it acts by block-
ing virus particle attachment (Nisole et al. 2002); lactofer-
rin (LF), found in mammalian secretions and blood, inhib-
its proliferation of cancerous mammary gland epithelial 
cells and also manifests a potent anti-viral activity against 
HIv and human cytomegalovirus (Legrand et al. 2004); 
AS1411, a 26-mer unmodified guanosine-rich oligonucleo-
tide, induces growth inhibition of cancer cells in vitro and 
shows inhibition of human tumor xenografts in vivo (Ireson 
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and Kelland 2006); guanosine-rich quadruplex-forming oli-
godeoxy nucleotides (GROs) are anti-carcinogenic ligands 
(Soundararajan et al. 2009); endostatin (eS), a 20-kDa 
C-terminal globular domain of the collagen XvIII, was iso-
lated from supernatant of a cultured murine hemangioendo-
thelioma cell line, and it specifically inhibits proliferating 
endothelial cell growth and angiogenesis (Shi et al. 2007); 
N6L is a proapoptotic molecule and a synthetic ligand of 
surface nucleolin that inhibits the anchorage-dependent 
and anchorage-independent growth of cancer cell lines and 
angiogenesis (Destouches et al. 2011).
As for disease-related ligands, their functions are var-
ied. Ligands that do not yet show carcinogenic or anti-
carcinogenic activities are grouped among the disease-
related ligands, derived from various sources: Lipoproteins 
contained in apoB and apoe bind to surface nucleolin of 
HepG2 cells, which act as LDL receptors (Semenkovich 
et al. 1990); laminin is a potent promoter of neurite out-
growth (Kleinman et al. 1991); fructosyllysine is the main 
glucose adduct in the extracellular proteins formed by a 
condensation between ε-amino group of lysine and glu-
cose by Amadori rearrangement and is found in human 
monocytes and monocyte-like cell line U937 (Krantz et al. 
1995); group B coxsackieviruses (CvB) are enteroviruses 
of the family Picornaviridae and important human patho-
gens (de verdugo et al. 1995); factor J (FJ), a soluble mol-
ecule found in urine and serum, is a complement inhibitor 
that regulates the pathways of a complement (Larrucea 
et al. 1998); HIv infects CD4+ target cells by fusion of the 
viral and cellular membranes through the external envelope 
glycoprotein gp120 (Nisole et al. 1999); elongation factor 
Tu (eF-Tu) of Francisella tularensis is a causative agent of 
tularemia that facilitates invasion of host tissue (Barel et al. 
2008); intimin-γ is an outer membrane protein of entero-
hemorrhagic Escherichia coli (eHeC) O157:H7 that colo-
calizes on the surface of Hep-2 cells with nucleolin (Sin-
clair and O’Brien 2002); human respiratory syncytial virus 
(RSv) causes an infectious disease worldwide, and it inter-
acts with host-cell nucleolin through viral fusion envelope 
glycoprotein (Tayyari et al. 2011); amyloid-β peptide 1-42 
(Aβ42) plays a key role in neurotoxicity of Alzheimer’s 
disease, and it strongly binds to nucleolin, although Aβ40 
is weakly bound (Ozawa et al. 2013). In this paper, we will 
discuss various kinds of ligands and surface nucleolin in 
focusing on carcinogenic and anti-carcinogenic activities.
TNF‑α as an endogenous tumor promoter
A tumor promoter induces clonal growth of initiated cells, 
resulting in tumor development. 12-O-tetradecanoylphor-
bol-13-acetate (TPA), teleocidin, and aplysiatoxin—the lat-
ter of which are structurally different from TPA—similarly 
induced potent tumor-promoting activity on mouse skin 
initiated with 7,12-dimethylbenz[a]anthracene (DMBA), 
mediated through activation of protein kinase C (Fujiki 
and Sugimura 1987). Moreover, okadaic acid and calycu-
lin A, which are potent inhibitors of protein phosphatases 
1 and 2A, are newly identified tumor promoters as potent 
as TPA on mouse skin initiated with DMBA (Fujiki and 
Suganuma 1993). In light of our evidence, we decided to 
look at endogenous tumor promoters in human carcinogen-
esis, focusing on the inflammatory cytokines. Our reasons 
are based on the “inflammation theory” of Rudolf virchow 
from Berlin (virchow 1858) and the carcinogenesis experi-
ment on rabbit ear with coal tar of Katsusaburo Yamagiwa 
and Koichi Ichikawa in Tokyo (1915; Fujiki 2014). Their 
contributions led us to our current understanding that the 
relationship between inflammation and tumor development 
is strongly associated with up-regulation of NF-κB at the 
molecular level (Fujiki et al. 2013). we were fortunate to 
be able to demonstrate that the proinflammatory cytokine 
TNF-α induces transformation of BALB/3T3 cells initiated 
with 3-methylcholanthrene (MCA) (Komori et al. 1993), 
which showed that TNF-α is the essential cytokine in tumor 
promotion since okadaic acid did not show any tumor-
promoting activities in TNF-α-deficient (TNF-α−/−) mice 
initiated with DMBA (Suganuma et al. 1999). Our further 
experiments revealed that TNF-α is strongly induced in 
organs of rodents by treatment with various tumor promot-
ers, such as microcystin-LR and nodularin, and that the 
inflammatory cytokines and chemokines, such as TNF-α, 
IL-1 and IL-6, are also thought to have tumor-promoting 
activities in human cancer development (Suganuma et al. 
2002; Fujiki and Suganuma 2011). Based on all of these 
results, we found a tumor promoter gene in H. pylori 
genome that induces TNF-α gene expression.
TNF‑α‑inducing protein (Tipα) of H. pylori
Helicobacter pylori membrane protein 1 (HP-MP1), one 
of the TNF-α-inducing proteins, has a molecular weight 
of 16 kDa, and its structure is not related to any virulence 
factors of H. pylori (Yoshida et al. 1999). The transfection 
of HP-MP1 gene into Bhas 42 cells, the putative initiated 
cells (v-Ha-ras-transfected BALB/3T3 cells), induced 
TNF-α gene expression with the levels ranging from 12.2- 
to 27.0-fold higher than the basal levels of the parental 
Bhas 42 cells, and the transfected cells induced morpho-
logical changes in transformation (Suganuma et al. 2001). 
Because the Bhas 42 cells containing HP-MP1 gene had 
shown strong tumorigenicity in nude mice (Fig. 1), we con-
cluded that HP-MP1 protein induced TNF-α gene expres-
sion and TNF-α production in cooperation with v-Ha-ras 
gene product. To generalize the concept of TNF-α-inducing 
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protein as a tumor promoter, we discovered HP0596 gene, 
from H. pylori strain 26695, in silico from the complete 
genome sequence (Suganuma et al. 2005). HP0596 gene 
was 94.3 % homologous to HP-MP1 gene; the deduced 
amino acid sequence revealed that HP0596 protein has 
172 amino acids with 19 kDa. we therefore designated 
HP0596 protein as the TNF-α-inducing protein (Tipα): The 
secreted amount of Tipα was determined using 28 clinical 
isolates of H. pylori obtained from 17 gastric cancer and 
11 chronic gastritis patients. Clinical isolates from cancer 
patients secreted Tipα at 1.4–13.4 relative units, and those 
from gastritis patients secreted it at 0.8–6.7 relative units, 
suggesting that Tipα induces cancer development in human 
stomach infected with H. pylori. All tested strains of H. 
pylori secreted both 38-kDa (dimer) and 19-kDa (mono-
mer) proteins in the medium, without dithiothreitol, in a 
manner independent of type Iv secretion system of cagA 
(Suganuma et al. 2008). To study the molecular mecha-
nisms, we made both recombinant Tipα protein (rTipα) 
and recombinant Tipα protein 6 amino acids deleted from 
N-terminal 2-7 (rdel-Tipα) as control, the latter of which 
lacks two cysteine residues, C5 and C7 (Suganuma et al. 
2005).
The quaternary structure of rdel-Tipα showed that rdel-
Tipα monomer A interacts with another monomer B, to 
form a heart-shaped dimer, and their circular dichroism 
spectra suggested that the structures of rdel-Tipα and Tipα 
homodimers are very similar (Tsuge et al. 2009). encour-
aged by the above-mentioned results, we studied the spe-
cific binding protein for Tipα in mouse gastric cancer cell 
line MGT-40, using fluorescein isothiocyanate (FITC)-
labeled rTipα. The specific binding of FITC-rTipα to MGT-
40 cells became saturated at a concentration of 5.0–7.5 μM, 
and this specific binding was inhibited by nonlabeled rTipα 
(IC50 1.9 μM), less weakly inhibited by rdel-rTipα (IC50 
20.0 μM). In addition, treatments of MGT-40 cells with 
FITC-rTipα at 37 or 4 °C showed that FITC-rTipα internal-
ized into MGT-40 cells in a temperature-dependent manner 
(Suganuma et al. 2008). The results show that a dimer of 
rTipα with disulfide bonds binds to a receptor of Tipα on 
MGT-40 cells and that the receptor-binding complex with 
rTipα induces TNF-α and chemokine gene expressions in 
the nuclei of MGT-40 cells (Kuzuhara et al. 2007; Suga-
numa et al. 2012).
Surface nucleolin as a receptor for Tipα of H. pylori
To identify the specific rTipα-binding protein, we made 
rTipα-FLAG and rdel-Tipα-FLAG, both of which carry a 
His-tag in the N-terminal and a FLAG-tag in the C-termi-
nal regions: rTipα-FLAG and rdel-Tipα-FLAG perform 
the same biological activities as rTipα and rdel-Tipα. After 
cell lysates of mouse gastric cancer cell line MGT-40 were 
incubated with rTipα-FLAG or with rdel-Tipα-FLAG in 
vitro at 4 °C for 2 h, the polypeptides that coimmunopre-
cipitated with rTipα-FLAG—but not rdel-Tipα-FLAG—
were further subjected to tryptic digestion and LC–MS 
analysis. Since 88- and 40-kDa polypeptides that we 
obtained showed an identical peptide sequence to that of 
mouse nucleolin, their polypeptides were further subjected 
to immunoblot analysis with anti-nucleolin antibody. Pull-
down assay using recombinant human nucleolin fragment 
showed that Tipα directly binds to nucleolin, and additional 
experiments with cell fractionation and flow cytometry 
confirmed that the 88-kDa polypeptide is nucleolin, which 
is located on the cell surface of MGT-40: This was the first 
evidence that surface nucleolin acts as a Tipα receptor of 
H. pylori (watanabe et al. 2010b). The results provide a 
new possibility to study gastric carcinogenesis of H. pylori 
using a nucleolin and Tipα complex.
Role of surface nucleolin in gastric carcinogenesis 
in humans
The cell lysates of five human gastric cancer cell lines 
were divided into membrane, cytosolic, and nuclear frac-
tions, and each fraction was then subjected to SDS–PAGe 
and further immunoblotted with anti-nucleolin antibody. 
The amount of surface nucleolin was found to be large in 
MKN-45 (poorly differentiated adenocarcinoma), KATOIII 
(signet ring cell carcinoma), MKN-74 (moderately dif-
ferentiated adenocarcinoma), and AGS (adenocarcinoma) 
cells; the amount was small in MKN-1 (adenosquamous 
carcinoma) cells, but all five cell lines contained similar 
amounts of nucleolin in the whole cell lysates (watanabe 
et al. 2010a). In addition, the presence of surface nucleolin 
Fig. 1  Tumor development of Bhas 42 cells containing HP-MP1 
gene in nude mice. Tumor-bearing mouse implanted with Bhas 42 
cells containing HP-MP1 gene 28 days later
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was confirmed in all the cell lines by flow cytometry after 
they were incubated with anti-nucleolin antibody (anti-
NUC295) or with preimmune serum in the presence of 
Alexa Fluor 488-conjugated goat anti-rabbit IgG. It is of 
interest to note that the amount of surface nucleolin in the 
normal epithelial membrane fraction of mouse glandular 
stomach is much lower than that in malignant MGT-40 
cells, indicating that translocation of nucleolin to the cell 
surface occurs during carcinogenesis, making for easier 
binding to Tipα (watanabe et al. 2010a). The results are 
well supported by previous evidence showing that the pres-
ence of surface nucleolin in various types of cells is closely 
associated with cell proliferation (Hovanessian et al. 2000).
The anti-carcinogenic aptamer AS1411, a DNA aptamer 
of 26-mer unmodified guanosine-rich nucleotide, binds to 
nucleolin and results in inhibition of nucleolin functions 
(Ireson and Kelland 2006; Soundararajan et al. 2009). we 
studied the inhibitory effects of AS1411 on cell growth 
of five human gastric cancer cell lines, and their IC50 val-
ues were in the range of 2.3 to >20.0 μM, whereas con-
trol cytidine-rich oligonucleotide (CRO) of AS1411 did 
not show any inhibition. In addition, the incorporation of 
FITC-AS1411 into the cells of human gastric cancer cell 
line MKN-45 was detected within 2 h, and the incorporated 
FITC-AS1411 had colocalized with nucleolin in cytosol 
and nucleoli (watanabe et al. 2010a).
To demonstrate the direct involvement of nucleolin in 
cell migration induced by rTipα, the cells of human gastric 
cancer cell line MKN-1 were transfected with small inter-
fering RNAs, nucleolin-targeted siRNA-n1 and siRNA-n2. 
The result was 50 % reduction in the nucleolin in their cell 
lysates, whereas transfection with negative control siRNA-
nc did not reduce nucleolin (Fig. 2a). when cell lysates 
of the transfected cells were fractionated into membrane, 
cytosol, and nuclear fractions, transfection with siRNA-n1 
and siRNA-n2 resulted in the reduction in nucleolin in the 
membrane fraction compared with that in the cytosol and 
nuclear fractions (Fig. 2b). Transfections with siRNA-n1 
and siRNA-n2 into MKN-1 cells also inhibited cell migra-
tion induced by rTipα 60.4 and 86.1 %, respectively, while 
inhibition with siRNA-nc as control was marginal (Fig. 3) 
(watanabe et al. 2013). All the results showed that trans-
fection with siRNA-n1 and siRNA-n2 significantly inhib-
ited the effects of rTipα, including cell migration, elonga-
tion, cell stiffness, and eMT, due to knockdown of surface 
nucleolin, which indicated that surface nucleolin is directly 
both a carcinogenic mediator for Tipα and an anti-carcino-
genic mediator for AS1411.
Fig. 2  Inhibition of nucleolin 
expression in MKN-1 cells 
transfected with nucleolin-
targeted siRNAs. a Nucleolin 
expression was determined in 
whole cell lysates. The cells 
were treated with nontransfec-
tion, siRNA-nc as control, and 
two nucleolin-targeted siRNAs, 
siRNA-n1 and siRNA-n2. 
b Nucleolin expression was 
determined in membrane, 
cytosol and nuclear fractions in 
nontransfected and transfected 
cells, and nucleolin expres-
sion was compared with that 
of eGFR, HSP90, and lamin B 
proteins
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Surface nucleolin on HeLa CD4+ cells as a receptor 
of HIV‑1 particle
HIv is an envelope virus that infects target cells by the 
fusion of viral and cellular membranes. Hovanessian and 
his colleagues first found that the binding of HIv-1 parti-
cle to nucleolin on HeLa CD4+ cells was inhibited by two 
substances: antibody against v3 loop domain of viral exter-
nal envelope glycoprotein gp120 of HIv-1, which contains 
a hypervariable region of about 36 amino acids referred to 
as the v3 loop, and by v3 loop domain-mimicking pseu-
dopeptide 5[Kψ(CH2N)PR]-template-assembled synthetic 
peptide (TASP). The team also obtained the results showing 
that peudopeptide 5[Kψ(CH2N)PR]-TASP (HB-19) inhib-
its HIv entry into CD4+ cells mediated through nucleolin 
(Callebaut et al. 1998).
Based on this evidence, their study was extended to 
examine inhibitory effects on cell growth and angiogen-
esis with HB-19, since surface nucleolin is implicated 
in growth of cancer cells and angiogenesis. when human 
breast cancer cell line MDA-MB-231 was injected into the 
mammary fat pad of female nude mice, palpable tumors 
approximately 40 mm3 in volume developed 2 weeks later, 
and the mice were randomly separated into three groups: 
The first group was given HB-19 (5 mg/kg) for 6 weeks; 
the second group was treated with tamoxifen (10 mg/kg) 
for 6 weeks; and the third group was given PBS only. Treat-
ment with HB-19 reduced tumor weight >95 %, and that 
with tamoxifen reduced it 80 %. In the next experiments, 
MDA-MB-231 cell line was inoculated into the flank of 
female athymic nude mice: Intraperitoneal administra-
tions of HB-19 (i.p., 10 mg/kg) three times per week for 
a period of 28 days resulted in more than 95 % reduc-
tion in tumor volume throughout the experiment, and that 
of subcutaneous administrations (s.c.) showed similarly 
strong reduction (Destouches et al. 2008) (Fig. 4). In this 
carcinogenesis experiment, it is not known which kinds 
of carcinogenic ligands were produced in MDA-MB-231 
cells, but we assume that endogenous inflammatory 
cytokines and chemokines, which are able to bind to nucle-
olin, were probably involved in this tumor growth, since 
tumor promotion and progression are induced by inflam-
matory proteins (Fujiki et al. 2013). In addition, HB-19 
treatment inhibited in vivo angiogenesis in chick embryo 
chorioallantoic membrane assay, so the results indicate that 
surface nucleolin itself is also a target for cancer treatment 
(Destouches et al. 2008).
Anti-carcinogenic activity of HB-19 was next examined 
using rhabdoid tumor cell line G401 derived from wilms’ 
tumor in nude mice. Nontreated G401 cells as control and 
G401 cells pretreated with HB-19 were separately inocu-
lated into nude mice. The average tumor weight (5 mice) 
in control group was 2.36 ± 1.25 g at day 50 of the experi-
ment, whereas that of three mice in HB-19-treated group 
was 0.32 ± 0.18 g (Krust et al. 2011b). The results show 
that HB-19 treatment inhibited the malignant growth of 
wilms’s tumor cells.
Retardation of melanoma development in RET 
transgenic mice by HB‑19
MT/ret+/− transgenic mice (ReT mice) expressing the rfp-
ret oncogene develop a spontaneous melanoma that consti-
tutively enhances cReT protein expression in the develop-
ment of melanoma in ReT mice (Kato et al. 1998; Ohshima 
et al. 2010). To study the anti-carcinogenic activity of HB-
19, 10-day-old ReT mice were treated with 50 μg HB-19, 
Fig. 3  Inhibition of Tipα induced cell migration in MKN-1 cells 
transfected with nucleolin-targeted siRNAs
Fig. 4  Inhibition of tumor growth of human breast cancer cell line 
MDA-MB-231 in xenograft nude mouse model treated with PBS 
alone (filled square), HB-19 s.c. (filled circle), and HB-19 i.p. (open 
circle)
696 J Cancer Res Clin Oncol (2014) 140:689–699
1 3
5 i.p. injections for the first week, 100 μg for the second 
week, and 200 μg for the rest of the experiment, and con-
trol mice received PBS only. The first melanoma in control 
group appeared at day 50 in the skin, while that in the HB-
19-treated group was found at day 75, suggesting that HB-
19 treatment delayed the onset of melanoma development 
(Fig. 5a). when the first appearance of a large melanoma 
(over 60 mm2) was next compared between the two groups, 
the difference was significant: Large melanoma of control 
group started to develop from day 75, whereas that of the 
HB-19-treated group started from day 190, so HB-19 treat-
ment delayed the development of melanoma, but did not 
eradicate it (Fig. 5b) (el Khoury et al. 2010). Melanoma 
cells have malignant features in which they metastasize to 
lymph nodes, mediastinum, and lungs. eight of 11 control 
mice (72.7 %) showed either retroperitoneal metastasis or 
mediastinal adenopathies, whereas only three of nine mice 
(33.3 %) in the HB-19-treated group showed visceral or 
lung metastasis: HB-19 treatment partly prevented metas-
tasis of melanoma cells in ReT mice. Although the cReT 
protein is involved in the development of melanoma, it is 
not yet known whether it binds to surface nucleolin. In 
addition, the expression of MMP-2, MMP-9, and TNF-
α genes is significantly reduced in melanoma recovered 
from ReT mice treated with HB-19: HB-19 seems to have 
potential for cancer treatment and prevention. The results 
strongly support the conclusion that surface nucleolin 
mediates the anti-carcinogenic activity of HB-19, since 
HB-19 binds to RGG domain at the C-terminal end of 
nucleolin (el Khoury et al. 2010).
Discussion
The function of surface nucleolin is now a hot topic in can-
cer research. Since numerous ligands are derived from vari-
ous sources (Table 1), this paper discusses the interactions 
between surface nucleolin and Tipα of H. pylori as a model 
of human gastric carcinogenesis, and also the interaction 
between surface nucleolin and HB-19, an anti-HIv pseu-
dopeptide, as a model of anti-carcinogenesis. The signifi-
cance of tumor progression is the induction of eMT pheno-
types in human cancer cells, i.e., cancer cells shut down the 
expression of numerous epithelial cell markers and induce 
the expression of mesenchymal proteins associated with 
metastatic states. Based on evidence showing that cells 
transfected with nucleolin-targeted small interfering RNAs 
resulted in inhibition of eMT phenotypes, including cell 
migration and elongation, experiments have clearly demon-
strated that the eMT induced by Tipα is mediated through 
surface nucleolin (watanabe et al. 2013).
The anti-carcinogenic activity of HB-19 is encourag-
ing, as is that of aptamer AS1411. The binding affinity 
(Kα value) of HB-19 to v3-Bps containing nucleolin is 
9.6 × 109 M−1, Kα value sufficient to inhibit HIv entry to 
the cells (Callebaut et al. 1998). The results strongly sup-
port evidence showing that HB-19 inhibits tumor develop-
ment in xenograft nude mouse models, and we assume that 
the mechanisms of anti-carcinogenic activity are dependent 
on the competitive inhibition by HB-19 and AS1411 of var-
ious endogenous inflammatory carcinogenic ligands bind-
ing to nucleolin in vivo. Inhibitors of molecular interaction 
between surface nucleolin and its ligands have recently 
been reviewed looking at anti-carcinogenic activity (Kout-
sioumpa and Papadimitriou 2013).
It is remarkable that surface nucleolin binds to numer-
ous ligands, such as DNA and RNA. An NMR study on 
the interaction of nucleolin with RNA revealed that the 
first two of four RNA-binding domains (RBDs) of nucleo-
lin are responsible for the binding of nucleolin recognition 
element (NRe) of RNA molecule, because RBD1, RBD2, 
and the linker of nucleolin form a molecular clamp: NRe is 
sandwiched between RBD1 and RBD2 (Allain et al. 2000). 
If so, we can assume that the molecular clamp receives 
numerous ligands, including AS1411 (Arumugam et al. 
2010).
Fig. 5  Inhibition of spontane-
ous melanoma development in 
ReT mice by injections with 
HB-19. a Onset of first mela-
noma with HB-19 (dashed line) 
and nontreated control (dotted 
line), p < 0.001, b onset of large 
melanoma (>60 mm2) with HB-
19 (dashed line) and nontreated 
control (dotted line), p < 0.001
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It is difficult to show precisely how the dual functions 
of surface nucleolin are determined by ligands, or what the 
interaction of surface nucleolin with each protein of a nucle-
olin protein complex is; what we think is that the binding site 
of surface nucleolin is constantly occupied by endogenous 
ligands in vivo and that this leads to carcinogenic develop-
ment in humans. Moreover, the disease-related ligands need 
to be further investigated, because of significant ailments.
Since studies on the conditional nucleolin knockout 
cells and inactivation of nucleolin with siRNA in HeLa 
cells have indicated that nucleolin is absolutely required 
for proliferation and survival of these cells (Storck et al. 
2009; Ugrinova et al. 2007), it is not physiologically pos-
sible to completely block the function of surface nucleolin 
in the cells and in vivo. In order to use surface nucleolin as 
a therapeutic tool, the chemical and biochemical features of 
ligands and characterizations of surface nucleolin in target 
cells need to be further investigated. In summary, surface 
nucleolin is a carcinogenic, anti-carcinogenic, and disease-
related mediator, certainly worth intensive further study.
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